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Background: Anti-EGFR monoclonal antibodies have shown efficacy in the treatment of metastatic colorectal
cancer (mCRC). One of the mechanism is the antibody-dependent cell-mediated cytotoxicity (ADCC) in which Fc
region of the antibody binds to the Fc gamma receptors (FcγR) expressed by immune cells. The present study
investigated the association between single nucleotide polymorphisms of FcγRIIa and FcγRIIIa and clinical outcome
in mCRC treated with anti-EGFR antibodies.
Methods: Seventy-four consecutive patients with mCRC were analyzed. The genotypes for FcγRIIa-131 histidine
(H)/arginine (R), FcγRIIIa-158 valine (V)/phenylanaline (F) polymorphisms were evaluated by directly sequencing.
Multiplex allele-specific polymerase chain reaction was performed for FcγRIIIa-158 valine (V)/phenylanaline (F).
Correlations between FcγR polymorphisms, baseline patient and tumor features were studied by contingency tables
and the chi-square test. The Kaplan-Meier product limit method was applied to the progression-free survival (PFS)
curves. Univariate analysis was performed with the log-rank test. Cox proportional-hazards regression was used to
analyze the effect of multiple risk factors on PFS.
Results: FcγRIIIa polymorphisms were significantly associated with response to anti-EGFR-based therapy in
49 patients with kras wt tumors (p=0.035). There was not association with response for FcγRIIa polymorphisms.
Furthermore, obtained results suggested that prognosis is particularly unfavorable for patients carrying the
FcγRIIIa-158F/F genotype (median PFS V/V, V/F, F/F: 18.2 vs 17.3 vs 9.4 months). No prognostic ability was identified
for FcγRIIa polymorphisms.
Conclusions: In mCRC patients the presence of FcγRIIIa-F can predict resistance to anti-EGFR therapy and
unfavorable prognosis.
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Metastatic colorectal cancer (mCRC) is the second most
common cause of cancer death in the Western world
accounting for 40-50% of newly diagnosed patients [1].
Despite therapeutic advances, the prognosis for patients
with mCRC remains poor. However, the addition of
drugs such as irinotecan and oxaliplatin to 5-fluorouracil
(5-FU) has almost doubled the median survival from
12 months to 21 months [2]. Monoclonal antibodies
(mAbs) binding to the vascular endothelial growth factor
(VEGF) (bevacizumab) or the epidermal growth factor
receptor (EGFR) (cetuximab and panitumumab) have
shown efficacy in the treatment of mCRC increasing the
life expectancy of patients by more than 2 years [3].
While bevacizumab is administered in combination with
chemotherapy as a first-line treatment, anti-EGFR mAbs
find place in later-line treatments.
Cetuximab is an IgG1a chimeric mAb while panitumu-
mab is a fully human IgG2 mAb; they bind to EGFR and
block the binding of its natural ligands, preventing lig-
and dependent homodimerization and activation of
intracellular cascades that control cellular proliferation,
adhesion, angiogenesis, and apoptosis. Anti-EGFR mAbs
have proven to be effective in combination with chemo-
therapy or as single agents for treatment of mCRC [3].
Recent evidences showed that mCRC responds differently
to EGFR-targeted agents on genetic basis that involve also
the EGFR downstream effectors (i.e. kras, braf, PIK3CA
and PTEN) [4]. Although largely unexplored, monoclonal
antibodies also induce antibody-dependent cell-mediated
cytotoxicity (ADCC) [5-8]. ADCC is induced through the
interaction of the Fc region of the mAb with the Fc
gamma receptor (FcγR) expressed by effector cells (i.e.
natural killer-NK-lymphocytes, monocytes/macrophages).
Polymorphisms have been demonstrated on genes encod-
ing for the activating receptors FcγRIIa (CD32, mainly
expressed on macrophages) and FcγRIIIa (CD16, expressed
on NK cells and macrophages) [9], affecting their affinity to
human IgG: a histidine (H)/arginine (R) polymorphism at
position 131 for FcγRIIa and a valine (V)/phenylalanine (F)
polymorphism at position 158 for FcγRIIIa. Based on the
different affinities, patients harboring FcγRIIa-131H/H and
FcγRIIIa-4 158V/V genotypes would be expected to me-
diate a more efficient ADCC antitumor response. Clinical
studies utilizing rituximab in the treatment of B-cell non-
Hodgkin’s lymphoma have shown that FcγRIIa-131H/H
and FcγRIIIa-158V/V genotypes were associated with
better clinical outcome [10,11]. Patients with 158V/V
and/or 131 H/H had a significantly higher response rate
than patients without either genotype (59% vs 18%). The
progression-free survival (PFS) estimate of patients with
158V/V and/or 131H/H allele was also significantly longer,
with median PFS of 445 and 140 days for the two groups,
respectively [11]. Nevertheless it was shown that whenCT is added to Rituximab the predictive value of FCGR
polymorphisms was lost probably due to the high efficacy
of CT [12]. In trastuzumab-treated metastatic breast
cancer, ADCC analysis showed that the combination of
158 V/V and/or 131 H/H had a significantly higher
trastuzumab-mediated cytotoxicity than other genotypes
in addition to higher response rate and a longer PFS [13].
Contrasting results have been reported on the role of
FcγR polymorphisms in mCRC [14,15]. Recently, it was
described that FcγRIIa-131H/H and FcγRIIIa-158F/F
polymorphisms associated with better PFS in a series of
EGFR-expressing mCRC patients treated with single-agent
cetuximab [14]. Conversely, Bibeau et al. demonstrated a
favourable effect on PFS only for the FcγRIIIA-158V/V
genotype unrelated to the kras status [15]. The goal of
our study was to explore the association between FcγRIIa
and FcγRIIIa polymorphisms and the outcome of mCRC
patients treated with anti-EGFR-based therapies (cetuxi-
mab and panitumumab).Methods
Patient management and follow-up
Seventy-four stage IV CRC patients were studied at the
Division of Abdominal Medical Oncology of the National
Cancer Institute (Naples, Italy) from May 2007 to May
2009. Patients were eligible after specific discussion on the
study. Informed consent from each patient was sought.
The protocol was conducted according to a protocol
approved by the institutional review board/independent
ethics committee. Patients were routinely characterized
for kras mutational status [16]. All patients underwent to
sequential standard treatments based on chemotherapy
and/or biologic therapies (bevacizumab, cetuximab, pani-
tumumab). First and second-line chemotherapy (CT)
included the association of fluoropyrimidines (capecita-
bine or 5-fluoruracile) with oxaliplatin or irinotecan. The
chemotherapy regimen was based on patient's perform-
ance status, extent of disease, comorbidities, previous
treatments and individual preferences. Some selected
patients underwent pulmonary and/or liver metastasec-
tomies as established in a multidisciplinary team dis-
cussion. Bone metastases were treated with palliative
radiotherapy. Patients features are shown in Table 1.
Cetuximab or panitumumab were administered only in
patients with kras wilde-type (wt) tumors. All patients
underwent first-line chemotherapy, 54 patients (72.9%)
received a second-line chemotherapy and 22 (29.7%) a
third-line chemotherapy. Eight patients received pallia-
tive radiotherapy. Eleven patients with advanced disease
underwent to palliative resection of primary colonic
tumor. Metastasectomies before or after chemotherapy
were performed in 26 patients. Total body computed tom-
ography scan and CEA monitoring were done every three





















IN Female 57 Yes Colon 3 4 3 158V/V (G/G) 131H/H (A/A) 20,0 FU+IRI+BEV PR CET PR
MM Female 50 No Rectum 3 4 NA 158V/F (G/T) 131H/R (A/G) 12,1 CAPE+OXA+BEV NA CET SD
SU Male 38 No Rectum 2 3 2 158V/V (G/G) 131H/R (A/G) 17,9 FU+IRI+BEV PR CET PR
RAM Female 70 Yes Rectum 2 1 2 158V/F (G/T) 131H/H (A/A) 10,2 FU+OXA+BEV CR CET SD
AA Female 77 No Colon 3 4 3 158V/F (G/T) 131H/H (A/A) 6,9 FU+OXA+BEV SD CET SD
MC Male 67 No Rectum 3 4 4 158V/V (G/G) 131H/R (A/G) 6,6 CAPE+OXA+BEV PD CET SD
MU Male 82 NA Colon 2 3 3 158V/V (G/G) 131H/R (A/G) NP CAPE+OXA+BEV SD No NA
AN Female 76 No Colon 2 4 NA 158V/V (G/G) 131H/H (A/A) NP CAPE+OXA+BEV PR No NA
VA Female 60 No Colon 3 4 NA 158V/F(G/T) 131H/R (A/G) 12,1 CAPE+OXA+BEV PR No NA
GA Female 70 No Colon 3 4 4 158V/V (G/G) 131H/R (A/G) 18,2 CAPE+OXA PR CET SD
SA Female 62 NA Rectum 3 4 3 158V/F (G/T) 131H/R (A/G) 6,4 FU+IRI+BEV PD CET PD
PG Male 75 No Colon 3 1 2 158F/F (T/T) 131H/R (A/G) 14,8 FU+OXA PR PAN PR
LRB Male 61 No Colon 1 3 3 158F/F (T/T) 131H/R (A/G) 7,7 FU+IRI+BEV SD CET SD
VA Male 71 No Colon 2 4 NA 158V/V (G/G) 131H/R (A/G) 8,8 CAPE+OXA+BEV PD No NA
SG Male 55 No Colon 2 4 NA 158V/V (G/G) 131H/H (A/A) 19,7 FU+IRI+BEV PD No NA
MR Female 61 No Colon 3 4 NA 158V/V (G/G) 131H/R (A/G) 10,8 CAPE+OXA+BEV SD No NA
MMG Female 43 No Colon 2 3 4 158V/V (G/G) 131H/H (A/A) 16,1 FU+OXA+BEV PR PAN PR
MM Male 74 No Colon 2 4 3 158V/F (G/T) 131H/H (A/A) NP FU+IRI+BEV SD No NA
GM Male 72 No Rectum 3 4 NA 158F/F (T/T) 131H/R (A/G) 2,6 CAPE+BEV SD PAN NA
LCR Male 74 No Rectum 3 3 3 158V/V (G/G) 131H/R (A/G) 23,0 CAPE CR CET PR
BG Female 47 No Colon 3 4 NA 158F/F (G/T) 131H/R (A/G) NP CAPE+OXA+BEV CR No NA
LG Female 56 No Colon 3 3 3 158V/V (G/G) 131H/R (A/G) 22,4 FU+IRI+BEV PD CET SD
DMV Male 65 No Colon 2 3 3 158V/F (G/T) 131H/R (A/G) 22,8 CAPE+OXA+BEV PR CET PR
FA Female 66 No Colon 2 4 4 158V/F (G/T) 131H/H (A/A) 10,0 FU+IRI+BEV PR CET PR
GF Male 56 No Colon 3 4 NA 158V/F (G/T) 131H/H (A/A) NP FU+IRI+BEV PR No NA
MA Female 55 No Rectum 2 4 NA 158V/F (G/T) 131H/H (A/A) NP CAPE+OXA+BEV PR No NA
MMR Female 54 No Rectum 2 1 2 158V/F (G/T) 131H/H (A/A) NA FU+IRI+BEV SD No NA
LS Female 58 No Colon 3 1 NA 158V/F (G/T) 131H/R (A/G) 15,6 FU+IRI+BEV PR CET PR
CD Male 64 No Rectum 3 4 NA 158V/F (G/T) 131H/R (A/G) 7,0 FU+IRI+BEV CR CET PR
VE Female 56 No Colon 2 3 3 158V/F (G/T) 131H/H (A/A) 38,0 FU+IRI+BEV PR CET PR
VA Male 81 No Colon 2 4 NA 158V/V (G/G) 131H/R (A/G) 8,9 FU+IRI+BEV PR CET SD
CM Female 75 No Colon 2 2 3 158V/F (G/T) 131H/H (A/A) 9,8 CAPE+OXA+BEV SD PAN PR
IG Male 73 No Colon 3 3 NA 158V/F (G/T) 131H/H (A/A) 19,5 FU+IRI+BEV SD CET CR




















Table 1 Detailed characteristics of patients and tumors (Continued)
RO Female 47 No Rectum 2 3 4 158V/F (G/T) 131R/R(G/G) 9,2 CAPE+OXA PR CET SD
VA Male 79 No Colon 2 4 NA 158V/V (G/G) 131H/R (A/G) 13,3 FU+IRI+BEV PR CET SD
DFC Male 64 NA Colon 2 4 3 158V/F (G/T) 131H/R (A/G) 21,3 CAPE+BEV PR CET SD
EI Female 64 No Colon 2 4 NA 158V/F (G/T) 131H/H (A/A) 16,2 CAPE+OXA+BEV PR No NA
DAR Female 66 Yes Colon 2 4 NA 158V/F(G/T) 131H/H (A/A) NP CAPE+OXA+BEV CR No NA
BT Male 56 No Rectum 2 4 NA 158V/V (G/G) 131H/R (A/G) NP FU+IRI+BEV PR No NA
CAG Female 54 No Rectum 2 3 4 158V/V (G/G) 131H/H (A/A) 11,7 CAPE+IRI+BEV PR CET PR
DV Female 78 No Colon 3 3 3 158V/F (G/T) 131H/R (A/G) 43,6 FU+IRI+BEV PR CET PR
BG Male 65 No Colon 3 4 NA 158V/F (G/T) 131H/H (A/A) 18,3 FU+IRI+BEV SD CET PR
NG Male 80 No Colon 2 4 NA 158F/F (T/T) 131H/H (A/A) 5,4 FU PD No NA
NR Female 42 No Colon 3 4 NA 158V/F(G/T) 131H/R (A/G) 6,7 CAPE+OXA+BEV PD No NA
MR Male 60 No Colon 3 4 3 158V/F (G/T) 131H/R (A/G) 8,7 FU+IRI+BEV PR CET SD
SF Female 62 No Rectum 2 4 NA 158V/F (G/T) 131R/R(G/G) 14,2 CAPE SD CET SD
DCM Male 60 No Colon 2 4 NA 158V/F (G/T) 131H/R (A/G) 37,5 FU+IRI+BEV PR CET PR
CML Female 44 No Colon 3 3 3 158V/F (G/T) 131H/R (A/G) 29,3 CAPE+OXA+BEV CR CET PR
BM Male 66 No Rectum 3 4 NA 158V/V (G/G) 131H/R (A/G) 8,1 CAPE+BEV SD CET SD
MI Female 40 NA Colon 2 4 NA 158V/V (G/G) 131H/R (A/G) NP FU+IRI+BEV PR No NA
GC Female 57 No Rectum 2 4 NA 158V/V (G/G) 131H/H (A/A) NP CAPE+OXA+BEV PR No NA
SC Male 53 No Rectum 3 4 NA 158V/V (G/G) 131H/R (A/G) NP CAPE+OXA+BEV SD No NA
RR Male 77 No Colon 2 2 1 158V/F (G/T) 131H/R (A/G) 9,4 FU+OXA+BEV PR PAN SD
GA Female 70 No Colon 3 4 4 158V/V (G/G) 131H/R (A/G) 14,6 CAPE+OXA PR No SD
MP Male 78 No Colon 3 4 3 158V/F (G/T) 131H/R (A/G) 9,6 CAPE+OXA+CET SD CET SD
CM Male 67 No Rectum 3 3 3 158V/V (G/G) 131H/H (A/A) 43,6 IRI+CET CR CET SD
FR Female 55 Yes Rectum 3 4 NA 158V/V (G/G) 131R/R(G/G) 12,4 CAPE+OXA SD CET SD
GL Male 74 Yes Colon 2 4 NA 158V/V (G/G) 131H/H (A/A) NP FU+OXA+BEV PR No NA
TMA Female 66 No Colon 1 4 NA 158V/V (G/G) 131H/R (A/G) NP FU+IRI+BEV PR No NA
CF Female 71 NA Rectum 2 4 NA 158V/V (G/G) 131H/R (A/G) NP CAPE+IRI+BEV PR No NA
CE Female 55 No Colon 1 1 4 158V/V (G/G) 131R/R(G/G) 6,1 CAPE+IRI+CET SD CET SD
SME Male 63 No Colon 3 4 4 158V/V (G/G) 131H/R (A/G) NP CAPE+IRI+CET PR CET PR
GM Male 56 No Rectum 3 4 4 158F/F (T/T) 131H/H (A/A) 7,2 CAPE+OXA+CET PR CET PD
IP Male 69 No Rectum 3 4 NA 158V/V (G/G) 131H/H (A/A) 7,8 CAPE+OXA PR CET PR
TMR Female 68 Yes Colon 3 4 NA 158V/V (G/G) 131H/R (A/G) 8,8 CAPE+OXA+CET PD CET SD
PM Female 77 No Colon 1 3 3 158F/F (T/T) 131H/H (A/A) 9,4 CAPE+OXA CR CET PD
MG Male 64 No Rectum 3 4 NA 158V/F (G/T) 131H/H (A/A) 16,5 IRI+CET PD CET SD
MG Male 68 No Colon 3 4 NA 158V/F (G/T) 131H/H (A/A) 2,8 CAPE+OXA PD CET PD




















Table 1 Detailed characteristics of patients and tumors (Continued)
SS Male 82 No Rectum 3 4 NA 158V/F (G/T) 131H/R (A/G) 19,4 CAPE PR CET PD
FP Male 69 Yes Colon 3 4 NA 158V/F (G/T) 131H/R (A/G) 20,8 FU+IRI SD CET PR
PA Female 70 NA Colon 2 4 3 158V/F (G/T) 131H/H (A/A) 23,3 CAPE+OXA CR No NA
DLA Male 82 No Colon 3 3 2 158F/F (T/T) 131H/R (A/G) 28,0 CAPE+OXA SD CET PD
CT: Chemotherapy: NA: Not Assessable; NP: Not Progressed; CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease; PFS: Progression Free Survival; FU: Fluorouracile; IRI: Irinotecan;
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RECIST criteria. Patients with target metastatic lesions
restaged at the Radiology Unit were considered for re-
sponse evaluation.
Complete response (CR) was defined as complete dis-
appearance of all detectable evidence of disease on total
body computed tomography. Partial response (PR) was
defined as at least a 30% decrease in the sum of dia-
meters of target lesions. Stable disease (SD) was defined
as everything between 30% decrease and 20% growth of
tumor size. Progressive disease (PD) was defined as at
least a 20% increase in the sum of diameters of target
lesions. Two patients were lost at follow-up.
Analysis of FcγRIIa-H131R, FcγRIIIa-V158F polymorphisms
Genomic DNA was extracted from white blood cells
(WBCs) using a DNA extraction kit.(Qiagen,Valencia,
CA) and stored at −20°. FcγRIIa genotyping was per-




Figure 1 FcγRIIa determined by direct sequencing and FcγRIIIa alloty
direct sequencing: (a) Sequencing electropherogram obtained from a sample
obtained from a sample heterozygous for allele FcγRIIa 131H/R; (c) Sequenc
allele FcγRIIa 131R/R. Lower Panel. FcγRIIIa allotyping by allele-specific PCR
and V/V control and CTL- negative control were represented. Examples repr(PCR) method adapted from a previously established
protocol [17]. Briefly, PCR amplification was performed
in 50 μl reaction mixture containing 100 ng genomic
DNA, 0.4 mM of each primer, 0.4 mM dNTPs, 20
mM Tris–HCl, pH 9.0, 100 mM KCl, 0.1 mM EDTA, 1.0
mM DTT, 0.5% tween 20, and 1 U Taq DNA polymerase.
The program was performed in the thermal Cycler 2770
by Applied Biosystems and consisted of an initial de-
naturation step at 95°C for 50, followed by 36 cycles of
95°C for 30 seconds, 56°C for 40 seconds, 72°C for 40
seconds and a final elongation step at 72°C for 10 min-
utes. The primers used for PCR amplification were for-
ward primer 50-GGAGAAACCATCATGCTGAG-30 and
reverse primer 5’-CAATTTTGCTGCTATGGGC-30. The
resulting PCR product (289bp) was purified with the Mon-
tage SEQ96 Sequencing Reaction Cleanup Kits (Millipore)
and prepared to sequence through a second PCR reac-
tion using Big Dye Terminator v3.1 Cycle Sequencing Kit
by Applied Biosystems in forward and reverse directionc
ping by allele-specific PCR. v Upper Panel. FcγRIIa determined by
homozygous for allele FcγRIIa 131H/H; (b) Sequencing electropherogram
ing electropherogram obtained from a sample homozygous for
. 100bp ladder marker, FcγRIIIa genotypes direct sequenced F/F, V/F
esented respectively F/F (a), V/F (b) and V/V (c) patients.
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of 96°C for10 seconds, 56°C for 5 seconds and 60°C for
2 minutes). PCR product was purified with Montage
SEQ96 Sequencing Reaction Cleanup Kits (Millipore) and
direct sequencing was run with Applied Biosystems3130
Genetic Analyzers (Figure 1).
For FcγRIIIa-V158F polymorphism, allele-specific PCR
method was followed. Briefly, 100 ng of genomic DNA
was amplified using allele-specific common forward primer
50-TCCAAAAGCCACACTCAAAGAC-30 and reverse pri-
mer 50-CTGAAGACACATTTTTACTCCCAAAC-30. PCR
amplification was performed in 25 μl reaction mixture
containing 100 ng genomic DNA, 0.3 mM of each primer,
0.2 mM dNTPs, 20 mM Tris–HCl, pH 9.0, 100 mM KCl,
0.1 mM EDTA, 1.0 mM DTT, 0.5% tween 20, and 1 U
Taq DNA polymerase. The program was performed in the
thermal Cycler 2770 by Applied Biosystems and consisted
of an initial denaturation step at 95°C for 50, followed by
35 cycles of 94°C for 30 seconds, 64°C for 30 seconds,
72°C for 30 seconds and a final elongation step at 72°C for
10 minutes. Three DNA samples previously sequenced
FcgRIIIa-V/V158, FcgRIIIa-V/F158, FcgRIIIa-F/F158 were
run in all reactions (Figure 1). The reaction products
were run on 3% ethidium bromide-stained agarose gel.
Seventy-three base pair PCR fragment either positive for
valine (V) or F allele was visualized under UV light as
reported previously [18]. To confirm FcγRIIIa genotype
automatic sequencing was performed using forward pri-
mer 50- TGT AAA ACG ACG GCC AGT TCA TCA
TAATTC TGT CTT CT-30; reverse primer 50–CAG GAA
ACA GCT ATG ACC CTT GAG TGA TGG TGA TGT
TCA-30. The part of exon 4 which contains the poly-
morphic site was amplified by PCR using 100 ng genomic
DNA, 0.4 mM of each primer, 0.4 mM dNTPs, 20
mM Tris–HCl, pH 9.0, 100 mM KCl , 0.1 mM EDTA, 1.0
mM DTT, 0.5% tween 20, and 1 U Taq DNA polymerase.
The program was performed in the thermal Cycler 2770
by Applied Biosystems and consisted of an initial de-
naturation step at 95°C for 50, followed by 36 cycles
of 95°C for 30 seconds, 57°C for 30 seconds, 72°C for 30
seconds and a final elongation step at 72°C for 10 min-
utes. The PCR product was sequenced using the Big DyeTable 2 Response to anti-EGFR therapy according to FcγR pol
Total no.(%)
Response to anti-EGFR based chemotherapy




PTerminator v3.1 Cycle Sequencing Kit by Applied
Biosystems.Statistical analyses and data presentation
Associations between FcγR polymorphisms and clin-
ical pathologic variables were evaluated by χ2 test.
p < 0.05 was considered statistically significant. Geno-
type data for FcγR polymorphisms and clinic-
pathological variables were retrospectively collected and
associated with response to anti-EGFR-based therapy by
χ2 test with level of significance set at p < 0.05.
Progression-free survival (PFS) was defined as the time
elapsed from the treatment initiation and tumor pro-
gression or death from any cause. The Kaplan-Meier
product limit method was applied to graph PFS. Uni-
variate analysis was done with the log-rank test. Cox
proportional hazards regression was used to analyze the
effect of several risk factors on PFS. Risk factors (covari-
ates) were: age, sex, grading, response to I° line
chemotherapy, FcγR polymorphisms. Ninety-five percent
confidence intervals of hazard ratios were also reported.
No attempts were done to analyze overall survival be-
cause of low events. Seventy-two patients were analyzed
since two were lost at follow-up. Statistical analysis was
performed using the MedCalcW 9.3.7.0 and Excel
software.Results
Characteristics of patients and tumors
Seventy-four patients seen from May 2007 to May
2009 were studied for the FcγRIIa and FcγRIIIa poly-
morphisms through direct sequencing and allele spe-
cific PCR as reported in Figure 1. Patients features
are detailed in Table 1. Median age was 65 years.
Genders were equally represented. Twenty-six tumors
originated in the rectum 51.4% of patients had high-
grade (G3) disease. The majority of lesions presented
with a pT3 extent of invasion at diagnosis and 22
presented with pN+ disease. Fifty patients presented
with stage IV disease, 16 with stage III and 8 with
stage I/II. The majority of tumors (90.5%) did notymorphisms
FcγRIIIa FcγRIIa
V/V V/F F/F H/H H/R R/R
7 12 1 9 11 0
10 11 1 5 13 4
1 3 3 3 4 0
0.035 0.344
Table 3 Correlation between skin toxicity and response
to anti-EGFR therapy (A), and polymorphisms
Response to anti-EGFR therapy
CR PR SD PD P**
Skin toxicity grade*
Grade 1 0 3 7 5
Grade 2 0 4 11 2
Grade 3 1 12 4 0 0.005
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histology was pure colonic adenocarcinoma (Table 1).FcγRIIIa but not FcγRIIa polymorphisms were significantly
associated with response to anti-EGFR-based therapy
in kras wt tumors
Fifty patients were treated with anti-EGFR-based therapy
and forty nine were evaluable for clinical response
(according to RECIST criteria) and PFS. Forty-five
patients were treated with cetuximab, five with panitu-
mumab. The genotypic frequencies of FcgRIIIA and
FcgRIIa detected within the analyzed population were
36% VV, 54% VF ,10% FF and 36% HH, 56% HR, 8% RR,
respectively. The χ2 test showed that there were no sig-
nificant differences in the genotype frequencies (p=0.109
for V158F; p=0.183 for FcgRIIa) between patients and
healthy controls. The genotypic distributions were in
Hardy-Weinberg Equilibrium.
Objective responses according to FcγR polymorphisms
were shown in Table 2. FcγRIIIa but not FcγRIIa poly-
morphisms were significantly associated with response
to anti-EGFR-based therapy in kras wt tumors
(p=0.035). The mean number of anti-EGFR therapy
cycles were 15 (range: 5–27) considering panitumumab
as single administration every two weeks (one adminis-
tration=1 cycle) and cetuximab weekly (two administra-
tions=1 cycle). To evaluate skin toxicity and its
predictive role and correlation with FcgR polymorphisms
(21), the skin related toxicity was evaluated versus the
clinical response. A significant correlation was identified
( p= 0.005) between skin toxicity and clinical response
(Table 3) while no significant correlation was identified
between skin toxicity and the genotype distribution
(Table 4).Table 4 polymorphisms
V/V V/F F/F
Skin toxicity grade*
Grade 1 3 9 3
Grade 2 7 8 2
Grade 3 8 9 0
*According to Common Toxicity Criteria for Adverse Event v3.0 and defined as any
P** at Chi-Square test.FcγR polymorphisms predict PFS in mCRC patients
treated with anti-EGFR mAbs
The anti-EGFR treated patients were analyzed for PFS.
As of June 2011, after a median follow-up for alive
patients of 22.4 months, 43 patients (87.7%) had suffered
tumor progression and 19 (44.2%) had died. Median PFS
was 17.0 months. Analysis of prognostic factors for PFS
is summarized in Table 5. Grading, response to 1st-line
chemotherapy and FcγRIIIa polymorphisms had a sig-
nificant prognostic value with univariate analysis. No
prognostic ability was identified for FcγRIIa poly-
morphisms. The prognostic value of the grading (p=0.04,
HR: 1.83, CI: 1.01-3.31), response to I°-line chemotherapy
(p=0.0004,HR:1.86,CI:1.32-2.62) and FcγRIIIa (p=0.001,
HR:2.35; CI:1.37-4.01) was confirmed with multivariate
analysis (Table 5). Hazard ratios of relapse and pattern of
Kaplan-Meier estimated curves suggest that prognosis is
particularly unfavorable for patients expressing the
FcγRIIIa-158F/F genotype (median PFS V/V, V/F, F/F:
18.2 vs 17.3 vs 9.4 months) (Figure 2).Discussion
In this manuscript the value of the FcγRIIa-FcγRIIIa poly-
morphisms was retrospectively correlated to the efficacy
of anti-EGFR therapy in mCRC. FcγRIIIa polymorphisms
were significantly associated with response to anti-EGFR-
based therapy in 49 valuable patients with kras wt tumors.
The results suggested that prognosis is particularly unfavor-
able for patients expressing the FcγRIIIa-158F/F genotype
versus patients carrying a V allele (the FcγRIIIa-158F/V
or the FcγRIIIa-158V/V genotypes). On this issue, con-
flicting results were previously described: Bibeau et al.
showed a statistically significant difference in PFS in
69 mCRC patients treated with cetuximab plus irinotecan
carrying the the FcγRIIIa-158V/V genotype compared to
other combinations expressing an F allele while FcγRIIa
polymorphisms did not affect prognosis [15]. Conversely,
in a series of 39 EGFR-expressing mCRC patients treated
with single-agent cetuximab, Zhang et al. [14] found that
FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms were
independently associated with better PFS. However,
against their hypothesis, FcγRIIIa-158V/V genotype was
associated with more unfavorable clinical outcome. The
authors suggest that variants of human IgG1–binding sitesP** H/H H/R R/R P**
5 10 0
5 9 3
0.2707 7 9 1 0.4198
grade of rash/acne/dermatitis.
Table 5 Uni- and multivariate analyses for progression-free survival (PFS)
Events/Patients Median PFS(months) P1 HR2 95% CI3 P4
Covariate
Age (≤70 vs >70 years) 32/36 vs 11/13 17.0 vs 18.0 0.50 0.61 0.30-1.20 0.15
Sex (male vs female) 24/28 vs 19/21 18.3 vs 15.6 0.73 1.28 0.69-2.35 0.42
Grading (G1/G2 vs G3) 15/20 vs 28/29 17.3 vs 13.3 0.007 1.83 1.01-3.31 0.04
Response to 1st-line CT0 (CR vs PR vs SD vs PD) 7/8 vs 18/23 vs 12/12 vs 6/6 20.1 vs 20.0 vs 9.8 vs 7.6 0.0026 1.86 1.32-2.62 0.0004
FcγRIIIa (VV vs VF vs FF) 13/18 vs 25/26 vs 5/5 18.2 vs 17.3 vs 9.4 0.04 2.35 1.37-4.01 0.001
FcγRIIa (HH vs HR vs RR) 17/18 vs 23/27vs 3/4 16.1 vs 18.2 vs 13.3 0.61 1.19 0.72-1.96 0.49
P1 = Log Rank P.
HR2 = Cox regression HR.
CI3 = Confidence Intervals.
P4 = Cox’s Proportional Hazards Regression P.
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actions with activating (FcγRIIIa) or inhibitory (FcγRIIb)
receptors on effector cells.
In the present study a significant association between
FcγRIIIa-158V/V genotype and response to anti-EGFR-
based chemotherapy was demonstrated in 49 kras wt
patients confirming that the expression of the allele F
predicts a worse response and a shorter PFS. In the
evaluated population, 49 patients, 5 (10.2%) carried the
FF genotype for FcγRIII and 4 of 49 (8.2%) the RR
genotype for FcγRII. These frequencies differ from
those previously reported. In particular, Carlotti et al.
investigated on 94 Italian patients affected by follicular
lymphoma and thus treated with Rituximab; they
reported 30 FF (32%) and 18 RR (19%) distribution
[12]. Bibeau et al. analyzed a cohort of European sub-
jects affected by mCRC-cetuximab treated, reporting
15 FF (22%) and 17 (28%) RR patients. Nevertheless,
comparing the allelic frequencies in a population of
168 healthy donors there were no significant differences
in the genotype frequencies (χ2 test p=0.109 for V158F;Figure 2 Progression-free survival curves according to FcγR polymorp
time elapsed between treatment initiation and tumor progression (a) FcγR
13 events) vs 18.2 months in H/R patients (27 patients, 23 events) vs 13.3 m
curves: p = 0.61. (b) FcγRIIIa: median PFS was 18.2 months in V/V patients (
25 events) vs 9.4 months in F/F patients (5 patients, 5 events); Log Rank tep=0.183 for FcgRIIa). Moreover we can also speculate
that, although the studied population represent 74 con-
secutive mCRC patients coming to our observation, they
all showed a good Performance Status (0–1) further
validated by the neoadjuvant treatment for 23 patients
(Fluopirimidine/ Irinotecan/ Bevacizumab) before hepatic
metastasectomy.
The role of ADCC induced by EGFR-specific mAbs
may prevent tumor outgrowth or metastasis in vivo, even
in cancers insensitive to EGFR signaling inhibition [19].
In fact, evidences accumulated on a complex patients
evaluation including the kras status but also EGF/EGFR
polymorphisms and downstream pathway mutations. To
date, unless a large number of patients have been treated
with mAbs there are still two crucial issues: i) a small per-
cent of kras mutated patients respond to cetuximab ther-
apy [3,4] and, ii) although kras wt tumors are potentially
sensitive to EGFR-targeted mAbs, not all respond to anti-
EGFR therapy for multiple target expression, amplifica-
tion or mutations downstream [4]. Blockade of signal
transduction may not be the only mechanism of actionhisms on 49 mCR Cpatients. Progression-free survival was defined as
IIa: median PFS was 16.1 months in H/H patients (18 patients,
onths in R/R patients (4 patients, 3 events); Log Rank test for three
18 patients, 13 events) vs 17.3 months in V/F patients (26 patients,
st for three curves: p = 0.04.
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colorectal cancer [20]. Cell-dependent lysis of target cells
mediated by mAbs in vitro and in animal models is a
crucial mechanism of action regulated by multiple
factors (i.e. FcγR on Dendritic Cells, T-helper system,
Tregs, B-cells, NK-cells inhibitory proteins, cytokines,
etc.). Currently, we are studying the correlation between
specific FCγR polymorphisms to in vitro ADCC efficacy
(Trotta et al., manuscript in preparation).
Conclusions
Although the exact role of FcγRIIIa-V158F polymorphism
and anti-EGFR therapy require more basic studies, the
presence of one allele F of the FcγRIIIa in mCRC patients
predicted poor response to anti-EGFR-based therapy and
worsen the prognosis.
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